Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

Abstract: This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.

Abstract: A nanobiocatalytic membrane for a filtration system is provided which includes a filtration membrane and a plurality of nanobiocatalyst nanoparticles associated with the membrane, each of the nanobiocatalyst nanoparticles including a core, a coating at least partially surrounding the core, and a plurality of nanobiocatalysts coupled to the coating. Each of the plurality of nanobiocatalysts includes an antibacterial nanoparticle comprising bismuth, and a quorum quenching agent coupled to the antibacterial nanoparticle. A nanobiocatalyst nanoparticle for use with a water purification system is also provided. A method of forming a nanobiocatalytic membrane for a filtration system and a method of using a nanobiocatalytic membrane in a filtration system are also provided.

Abstract: An active sitting chair is provided that encourages a sitter/user to sit actively by requiring balance adjustments and core engagement. The active sitting chair can be efficiently produced while being relatively sturdy and lightweight. The main body may be a monocoque shell that includes a rounded lower portion that contacts the surface the chair is on and promotes wobble of the chair when a sitter is seated on the chair. The chair may also include built-in handles for ease of lifting and a seat portion at the top of the chair that may include a cushion or similar component for increasing the stability and/or comfort of a sitter.

Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.

Abstract: Compositions and methods are provided for determining platelet reactivity where the levels of Fc?RIIa on the surface of platelets is measured and if the levels of Fc?RIIa are greater than a reference value, the platelets have enhanced reactivity.

Abstract: The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.

Abstract: Implementations described and claimed herein provide for modular snow and ice retention and mounting systems. In various embodiments, a bracket may comprise a mounting strap, a hybrid pad, a bracket assembly and a rod. The hybrid pad may comprise a face portion and a support portion. The face portion and the support portion may be operatively coupled together. The hybrid pad may be operatively coupled to the mounting strap. The face portion may comprise a stiffening rib. The stiffening rib may be defined in a front surface of the face portion. The stiffening rib may define a first load plane. The face portion may also define a first rod notch. The first rod notch may be defined on a first side of the face portion. The face portion may also define a second rod notch. The rod may be mountable to the hybrid pad.

Abstract: A pet ramp is provided having two panels in a collapsible arrangement, with a first panel having legs and a second panel able to be cantilevered from the first panel. The second panel extends beyond the legs and is pivotable to rest on any available surface. A stop is provided between the first and second panels to hold a cantilevered deployed position of the second panel.

Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

Abstract: A system that executes a process for mapping cardiac fibrillation and optimizing ablation treatments. The process, in some embodiments, includes: positioning a two dimensional electrode array to several locations in a patient's heart and at each location, obtaining a conduction velocity and a cycle length measurement from at least two local signals in response to electrical activity in the cardiac tissue. In some embodiments, a regional wavelength is calculated by multiplying the local conduction velocity with the local minimum cycle length. The system can then create a wavelength distribution map that identifies the location of the drivers in the heart. In certain embodiments, the system uses variability of conduction velocity and cycle length in an area to determine the driver type. In some embodiments, the system calculates average distance of drivers to non-conductive tissue boundaries. The system then selects ablation placements that maximize treatment efficacy while minimizing tissue damage.

Abstract: Cryptosporidium is a leading contributor to early childhood mortality, and fully effective treatment for this important infectious disease is lacking. A bicyclic azetidine compound series is disclosed having potent in vitro activity against all C. parvum isolates tested, comparable potencies against C. hominis and C. parvum, and cured cryptosporidiosis in highly susceptible immunosuppressed mice with once-daily dosing.

Abstract: Provided herein are compositions and methods relating to ?? T cells. Specifically, methods of screening samples for human ?? T cells surface ligands using a soluble human ?? T cell receptor tetramer are provided. Such ligands may be useful in the treatment of diseases, for example, cancer.

Abstract: An accessory for a solar panel assembly includes a bracket defining an elongated portion extending in a first direction and including a slot, a connector coupled to the bracket and configured to engage at least one panel frame of the solar panel assembly, and a fence member including a first portion and a second portion. The first portion including a planar surface oriented at an angle relative to the bracket portion, and the second portion includes a projection that removably engages the slot.